The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...
The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.
A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...
Nine states have been identified as being affected by the chocolate recall, but the products were available online so others ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
FRIDAY, Jan. 31, 2025 (HealthDay News) -- The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain ...
The Food and Drug Administration approved the pill from Vertex Pharmaceuticals for acute pain that often occurs after surgery ...
Federal officials approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with ...
Each year, about 125 million opioid prescriptions are written for Americans with pain caused by broken bones, burns, ...
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.
A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...
The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive. The Food and Drug ...